Navigation Links
New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia

--Study Used To Support FDA Approval of SEROQUEL XR--

WILMINGTON, Del., May 22, 2007 /PRNewswire-FirstCall/ -- AstraZeneca today announced that two analyses from a large-scale study that investigated the efficacy of SEROQUEL XR(TM) (quetiapine fumarate) Extended-Release Tablets, a once-daily medicine for the treatment of schizophrenia in adult patients, were presented today at the annual meeting of the American Psychiatric Association (APA). These analyses from the clinical trial data for SEROQUEL XR showed that it was effective versus placebo in patients with an acute exacerbation of symptoms of schizophrenia.(1,2)

On May 17, 2007, the U.S. Food and Drug Administration (FDA) approved SEROQUEL XR for the treatment of schizophrenia in adult patients.

"Both analyses show that SEROQUEL XR was superior to placebo, demonstrating it is another viable treatment option for schizophrenia," said Charles Schulz, MD, Professor and Head, Department of Psychiatry, University of Minnesota Medical School. "These analyses are significant because SEROQUEL XR may provide greater convenience and simplicity in patient treatment plans."

About large-scale study: Study 132

This six-week, double-blind, randomized, placebo-controlled study investigated the efficacy and safety of once-daily SEROQUEL XR. In this study, 588 patients with acute schizophrenia were randomized to receive either SEROQUEL XR at 400, 600, or 800 mg/day, the immediate release formulation of SEROQUEL(R) (quetiapine fumarate) at 400 mg/day (200 mg twice-daily), or placebo. The primary endpoint was assessed using the Positive and Negative Syndrome Scale (PANSS)(+).(1,2)

In the study, SEROQUEL XR was generally well-tolerated. SEROQUEL XR was administered once-daily at fixed doses, with dose escalation conducted over the initial three days (Day 1 = 300mg, Day 2 = 400 or 600mg, and Day 3=400, 600 or 800mg). The immediate release formul
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea

Post Your Comments:
(Date:11/30/2009)...30 Dr. Jocelyn Rapelyea, Associate...orge Washington University Medical Center in Washi...ified with Breast-Specific Gamma Imaging (BSGI) ca...r needle biopsy as well, as for pre-operative loca...ogical Society of North America (RSNA). ,, BSGI...
(Date:11/30/2009)...Nov. 30 Minimally-invasive procedu...rgery, particularly in oncology, cardiology and wo...or image-guided navigation expected to reach $600 ...ntages offered by minimally-invasive procedures, i...atient comfort and faster patient throughput. ,...
(Date:11/30/2009)...IV, Israel, November 30 Optoacoust...) dual channel microphone, the most advanced,optic...etic resonance imaging,(fMRI) environments. ,... step forward for fiber,optic microphone technolog...h,low-latency adaptive noise cancelling. The FOMRI...
Breaking Medicine Technology:Breast-Specific Gamma Imaging Identifies Occult Lesions Using Multi-Modality Imaging for Biopsy 2Philips Showcases Interventional Radiology Solutions to Support Growing Need For Minimally-Invasive Procedures 2Philips Showcases Interventional Radiology Solutions to Support Growing Need For Minimally-Invasive Procedures 3Philips Showcases Interventional Radiology Solutions to Support Growing Need For Minimally-Invasive Procedures 4Philips Showcases Interventional Radiology Solutions to Support Growing Need For Minimally-Invasive Procedures 5New Generation Noise Cancelling Optical Microphone Paves Way for Advanced Brain and Speech Research 2Killer bees may increase food supplies for native bees 10219 1Killer bees may increase food supplies for native bees 10219 2InVitria 26apos 3Bs Better Ingredients for Better Media to be Showcased at BPI 26apos 3B09 58682 1InVitria 26apos 3Bs Better Ingredients for Better Media to be Showcased at BPI 26apos 3B09 58682 2Maryland Residents Participate in Launch of National Video Campaign 3A Say Yes to Health Reform 58678 1Maryland Residents Participate in Launch of National Video Campaign 3A Say Yes to Health Reform 58678 2Maryland Residents Participate in Launch of National Video Campaign 3A Say Yes to Health Reform 58678 3
...ears of Treatment Presented at ICAAC/IDSA,2008 Ann...,Corporation (NYSE: SGP ) today reported a data a...al CCR5 receptor antagonist, demonstrated,sustaine...and was well,tolerated through up to four years of...ients. Vicriviroc was administered once-daily as a...
...udies affirmed the clinical benefits of,ACTEMRA -,...tudies,showed that patients who suffer from the de...itis (RA) achieved significant improvements in sig...lizumab) alone or in combination,with methotrexate...ts of,both studies will be presented as oral prese...
Other Medicine Technology:Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients 2Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients 3Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients 4Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients 5Analysis of Long-Term Vicriviroc Data Provides Evidence of Sustained Viral Suppression, Increased CD4 Cell Counts and Tolerability in Treatment-Experienced HIV-Infected Patients 6ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 2ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 3ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 4ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 5ACTEMRA (R) (tocilizumab) Significantly Reduced Signs and Symptoms of Rheumatoid Arthritis in Patients Who Failed Prior Treatments 6
(Date:11/30/2009)... , NASHVILLE, Tenn., Nov. 30 Du...t gifts for the holidays. For a loved one with Alz... members and friends oftentimes struggle with appr... , one of the leading providers of senior living r...d dementia care , offers these suggestions. ,, ...
(Date:11/30/2009)...CHICAGO, Nov. 30 Physicians at Bet...d today on results of a study demonstrating the po...ography (cCTA) by Rcadia,s COR Analyzer System... stenosis in hospital emergency department (ED ) p...ted system to enhance the use of cCTA has potentia...
(Date:11/30/2009)...ember 30, 2009A pet owner knows the enormous joy a...in troubled times. Most pets are considered import...ions. A growing body of research now documents the...nt, elderly care, mental illness, physical impairm...rehabilitation of incarcerated youth and adults. ,...
(Date:11/30/2009)...a helpings of gravy and dessert at the holiday tab...previously thought. According to a new research re...al ( http://www.fasebj.org ), a diet that is high...at ultimately cause our bodies to store too much f...hammy as the already difficult task of converting ...
(Date:11/30/2009)...le that worsens over time, so do knees, internal i...30 (HealthDay News) -- If you,re a middle-age week...or hockey rink, take note: A new study suggests th... of internal knee damage that could lead to osteoa...ccurred in middle-age people who showed no symptom...
Breaking Medicine News(10 mins):Health News:Gift Ideas for Loved Ones with Alzheimer's/Dementia 2Health News:Rcadia COR Analyzer(R) System Demonstrates Potential in Emergency Department Triage of Chest Pain Patients at Low to Moderate Risk of Coronary Artery Disease 2Health News:Rcadia COR Analyzer(R) System Demonstrates Potential in Emergency Department Triage of Chest Pain Patients at Low to Moderate Risk of Coronary Artery Disease 3Health News:The therapeutic benefits of the human-animal bond 2Health News:Western diets turn on fat genes 2Health News:Lots of Exercise in Midlife May Lead to Osteoarthritis 2Health News:Lots of Exercise in Midlife May Lead to Osteoarthritis 3
...ge for nicotine, rat study suggests , , MO...peptide receptor in the brain may be one way to qu...dy suggests. , Hypocretin-1, or Orexin A, a short ...he addictive chemical in tobacco, according to res...
...dicines for conditions that haven,t been studied t...ews) -- It,s called "off-label" prescribing, and i...rug to treat a disease or condition that,s differe...ittle evidence that using a drug for an unapproved...
... to treat anemia in patients with cancer are assoc...lood clots, at a similar rate as other treatments ... at the University of Rochester Medical Center. ,...leading causes of illness and death in people with...
... 24, 2008 A new study finds that youth population...dequate healthcare, and thus may fail to benefit f...Pediatric Blood & Cancer , finds that the patients... abnormally shaped red blood cells, affects close ...
...d by the termite Termes panamensis (Snyder), whi...rded, is sufficient to kill a would-be nest invade...l fellows at the Smithsonian Tropical Research Ins... Panama, established by a donation from the Frank ...
...erdam, The Netherlands and Sun City, AZ, USA -- A ...nal of Alzheimer,s Disease (Volume 15:3) suggests...ment Scale Cognitive (ADAS-Cog) may vary and poss...that contribute to variances seen in this assessme...
Other Medicine News:Health News:Molecular Switch in Brain May End Smokers' Cravings 2Health News:Study Calls for Greater Scrutiny of 'Off-Label' Drug Use 2Health News:Study Calls for Greater Scrutiny of 'Off-Label' Drug Use 3Health News:Study Calls for Greater Scrutiny of 'Off-Label' Drug Use 4Health News:Transfusions increase clot risk in hospitalized cancer patients 2Health News:Children with sickle cell disease receiving inadequate care 2Health News:Panamanian termite goes ballistic: Fastest mandible strike in the world 2Health News:Study suggests reliability of cognitive assessment tool varies widely 2
Power Supply EV265 for electrophoresis, 115V
EPS 601 Power Supply
...ly . The digital 200 V/2000 mA PSE Power Supply p...ts. • It is possible to run up to three SEA 2...atures: Direct reading of programmed preset and ac...ltage, mA and timer adjustable during a run •...
PowerPac HV Power Supply With Temperature Probe
Medicine Products: